Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Interim safety analysis supports continuation of phase II PROPEL trial

Jan. 2, 2008

PharmaMar's Yondelis completes requirements for launch in Spain

Dec. 31, 2007

Endocyte and R&D-Biopharmaceuticals enter tubulysin chemo agent agreement

Dec. 31, 2007

Cell Therapeutics completes Zevalin's acquisition for U.S. sales and marketing

Dec. 31, 2007

Phase I trial commences for Cougar Biotechnology's CB-3304

Dec. 31, 2007

Progen's phase III study of PI-88 for HCC open for recruitment

Dec. 31, 2007

Phase II IPI-504 trial initiated in patients with non-small cell lung cancer

Dec. 28, 2007

Peregrine gives update on its three lead clinical programs for bavituximab and Cotara

Dec. 28, 2007

Tissue-specific FAK gene deletion blocks mammary tumor progression

Dec. 28, 2007

Preliminary phase I results with AT-9283 in hematological malignancies encouraging

Dec. 28, 2007

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...